Maitake Beta-Glucan Enhances the Therapeutic Effect of Trastuzumab via Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity
This study demonstrates that the combination of trastuzumab and MD-Fraction exerts a greater antitumor effect than trastuzumab alone by enhancing ADCC, CDCC, and CDC in HER2-positive breast cancer.PMID:38616114 | DOI:10.1248/bpb.b23-00802 (Source: Biological and Pharmaceutical Bulletin)
Source: Biological and Pharmaceutical Bulletin - April 14, 2024 Category: Drugs & Pharmacology Authors: Yuki Masuda Shizuka Yamashita Yoshiaki Nakayama Ryohei Shimizu Morichika Konishi Source Type: research
Investigating the level of vitamin D receptor gene expression in two tumoral and healthy breast tissues in breast cancer patients and its association with prognostic factors
CONCLUSIONS: The expression level of VDR in healthy tissue was significantly higher than tumoral tissue. However, there was no significant relationship between VDR and tumor grade, HER2, ER, PR, LVI, LN, disease stage, age, and tumor size.PMID:38616231 | DOI:10.1186/s43046-024-00215-5 (Source: J Egypt Natl Canc In...)
Source: J Egypt Natl Canc In... - April 14, 2024 Category: Cancer & Oncology Authors: Maryam Bahador Marjan Saeedi Nejad Shahriar Dabiri Mohammad Hasan Larizadeh Maryam Fekri Soofiabadi Source Type: research
Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: activity and quality of life results of the GOIM 21003 trial
CONCLUSIONS: First line metronomic chemotherapy for HER2 negative ABC had similar clinical activity and quite better tolerability than standard schedule and could be considered a further treatment option when chemotherapy is indicated.PMID:38615483 | DOI:10.1016/j.breast.2024.103725 (Source: Breast)
Source: Breast - April 14, 2024 Category: Cancer & Oncology Authors: Laura Orlando Evaristo Maiello Michele Orditura Anna Diana Giuliano Antoniol Maria Grazia Morritti Michele Aieta Mariangela Ciccarese Salvatore Pisconti Roberto Bordonaro Antonio Russo Antonio Febbraro Paola Schiavone Annamaria Quaranta Chiara Caliolo Dar Source Type: research
Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: A real-world analysis of 871 patients treated with neoadjuvant therapy
CONCLUSIONS: HER2-positive breast cancer exhibited three distinct HR-specific subtypes with varying clinical manifestations and treatment responses. These findings suggest personalized treatment strategies considering ER and PR expression patterns, emphasizing the need for further investigations to unravel molecular traits underlying HER2-positive breast cancer with distinct HR expression patterns.PMID:38615482 | DOI:10.1016/j.breast.2024.103733 (Source: Breast)
Source: Breast - April 14, 2024 Category: Cancer & Oncology Authors: Haizhu Chen Xiujuan Gui Ziwei Zhou Fengxi Su Chang Gong Shunrong Li Wei Wu Nanyan Rao Qiang Liu Herui Yao Source Type: research
Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies
J Clin Med. 2024 Mar 24;13(7):1873. doi: 10.3390/jcm13071873.ABSTRACTHormone receptor (HR)-positive/HER2-positive breast cancer represents a distinct subtype expressing estrogen and progesterone receptors with an overexpression of HER2. Approximately 14% of female breast cancer cases are HER2-positive, with the majority being HR-positive. These tumors show a cross-talk between the hormonal and HER2 pathways; the interaction has implications for the treatment options for the disease. In this review, we analyze the biology of HR-positive/HER2-positive breast cancer and summarize the evidence concerning the standard of care o...
Source: Clinical Breast Cancer - April 13, 2024 Category: Cancer & Oncology Authors: Chiara Tommasi Giulia Air ò Fabiana Prattic ò Irene Testi Matilde Corian ò Benedetta Pellegrino Nerina Denaro Laura Demurtas Mariele Dess ì Sara Murgia Giovanni Mura Demi Wekking Mario Scartozzi Antonino Musolino Cinzia Solinas Source Type: research
The Modified Neo-Bioscore System for Staging Breast Cancer Treated with Neoadjuvant Therapy Based on Prognostic Significance of HER2-Low Expression
Conclusions: This study demonstrated that HER2-low tumor may exhibit prognostic significance. The innovative mNeo-Bioscore, based on a new classification of HER2 status, may serve as a prognostic staging system superior to Neo-Bioscore.PMID:38610617 | DOI:10.3390/jcm13071850 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 13, 2024 Category: Cancer & Oncology Authors: Yingying Zhao Xinru Chen Yaohui Wang Xueqing Zhang Jingsong Lu Wenjin Yin Source Type: research
The Modified Neo-Bioscore System for Staging Breast Cancer Treated with Neoadjuvant Therapy Based on Prognostic Significance of HER2-Low Expression
Conclusions: This study demonstrated that HER2-low tumor may exhibit prognostic significance. The innovative mNeo-Bioscore, based on a new classification of HER2 status, may serve as a prognostic staging system superior to Neo-Bioscore.PMID:38610617 | DOI:10.3390/jcm13071850 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 13, 2024 Category: Cancer & Oncology Authors: Yingying Zhao Xinru Chen Yaohui Wang Xueqing Zhang Jingsong Lu Wenjin Yin Source Type: research
Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies
J Clin Med. 2024 Mar 24;13(7):1873. doi: 10.3390/jcm13071873.ABSTRACTHormone receptor (HR)-positive/HER2-positive breast cancer represents a distinct subtype expressing estrogen and progesterone receptors with an overexpression of HER2. Approximately 14% of female breast cancer cases are HER2-positive, with the majority being HR-positive. These tumors show a cross-talk between the hormonal and HER2 pathways; the interaction has implications for the treatment options for the disease. In this review, we analyze the biology of HR-positive/HER2-positive breast cancer and summarize the evidence concerning the standard of care o...
Source: Clinical Genitourinary Cancer - April 13, 2024 Category: Cancer & Oncology Authors: Chiara Tommasi Giulia Air ò Fabiana Prattic ò Irene Testi Matilde Corian ò Benedetta Pellegrino Nerina Denaro Laura Demurtas Mariele Dess ì Sara Murgia Giovanni Mura Demi Wekking Mario Scartozzi Antonino Musolino Cinzia Solinas Source Type: research
The Modified Neo-Bioscore System for Staging Breast Cancer Treated with Neoadjuvant Therapy Based on Prognostic Significance of HER2-Low Expression
Conclusions: This study demonstrated that HER2-low tumor may exhibit prognostic significance. The innovative mNeo-Bioscore, based on a new classification of HER2 status, may serve as a prognostic staging system superior to Neo-Bioscore.PMID:38610617 | PMC:PMC11012268 | DOI:10.3390/jcm13071850 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 13, 2024 Category: Cancer & Oncology Authors: Yingying Zhao Xinru Chen Yaohui Wang Xueqing Zhang Jingsong Lu Wenjin Yin Source Type: research
Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies
J Clin Med. 2024 Mar 24;13(7):1873. doi: 10.3390/jcm13071873.ABSTRACTHormone receptor (HR)-positive/HER2-positive breast cancer represents a distinct subtype expressing estrogen and progesterone receptors with an overexpression of HER2. Approximately 14% of female breast cancer cases are HER2-positive, with the majority being HR-positive. These tumors show a cross-talk between the hormonal and HER2 pathways; the interaction has implications for the treatment options for the disease. In this review, we analyze the biology of HR-positive/HER2-positive breast cancer and summarize the evidence concerning the standard of care o...
Source: Clinical Genitourinary Cancer - April 13, 2024 Category: Cancer & Oncology Authors: Chiara Tommasi Giulia Air ò Fabiana Prattic ò Irene Testi Matilde Corian ò Benedetta Pellegrino Nerina Denaro Laura Demurtas Mariele Dess ì Sara Murgia Giovanni Mura Demi Wekking Mario Scartozzi Antonino Musolino Cinzia Solinas Source Type: research
Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies
J Clin Med. 2024 Mar 24;13(7):1873. doi: 10.3390/jcm13071873.ABSTRACTHormone receptor (HR)-positive/HER2-positive breast cancer represents a distinct subtype expressing estrogen and progesterone receptors with an overexpression of HER2. Approximately 14% of female breast cancer cases are HER2-positive, with the majority being HR-positive. These tumors show a cross-talk between the hormonal and HER2 pathways; the interaction has implications for the treatment options for the disease. In this review, we analyze the biology of HR-positive/HER2-positive breast cancer and summarize the evidence concerning the standard of care o...
Source: Clinical Breast Cancer - April 13, 2024 Category: Cancer & Oncology Authors: Chiara Tommasi Giulia Air ò Fabiana Prattic ò Irene Testi Matilde Corian ò Benedetta Pellegrino Nerina Denaro Laura Demurtas Mariele Dess ì Sara Murgia Giovanni Mura Demi Wekking Mario Scartozzi Antonino Musolino Cinzia Solinas Source Type: research
The Modified Neo-Bioscore System for Staging Breast Cancer Treated with Neoadjuvant Therapy Based on Prognostic Significance of HER2-Low Expression
Conclusions: This study demonstrated that HER2-low tumor may exhibit prognostic significance. The innovative mNeo-Bioscore, based on a new classification of HER2 status, may serve as a prognostic staging system superior to Neo-Bioscore.PMID:38610617 | PMC:PMC11012268 | DOI:10.3390/jcm13071850 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 13, 2024 Category: Cancer & Oncology Authors: Yingying Zhao Xinru Chen Yaohui Wang Xueqing Zhang Jingsong Lu Wenjin Yin Source Type: research
Cancers, Vol. 16, Pages 1490: Implementation and Evaluation of a Breast Cancer Disease Model Using Real-World Claims Data in Germany from 2010 to 2020
This study, the first to model breast cancer subtypes, stages, and outcomes using German claims data, provides valuable insights into real-world breast cancer epidemiology and demonstrates that this breast cancer disease model has the potential to be representative of treatment outcomes. (Source: Cancers)
Source: Cancers - April 13, 2024 Category: Cancer & Oncology Authors: Dominik Dannehl Alexandra von Au Tobias Engler L éa Louise Volmer Raphael Gutsfeld Johannes Felix Englisch Markus Hahn Sabine Hawighorst-Knapstein Ariane Chaudhuri Armin Bauer Markus Wallwiener Florin-Andrei Taran Diethelm Wallwiener Sara Yvonne Brucker Tags: Article Source Type: research
Targeted therapeutic options in early and metastatic NSCLC-overview
Pathol Oncol Res. 2024 Mar 28;30:1611715. doi: 10.3389/pore.2024.1611715. eCollection 2024.ABSTRACTThe complex therapeutic strategy of non-small cell lung cancer (NSCLC) has changed significantly in recent years. Disease-free survival increased significantly with immunotherapy and chemotherapy registered in perioperative treatments, as well as adjuvant registered immunotherapy and targeted therapy (osimertinib) in case of EGFR mutation. In oncogenic-addictive metastatic NSCLC, primarily in adenocarcinoma, the range of targeted therapies is expanding, with which the expected overall survival increases significantly, measure...
Source: Pathology Oncology Research - April 12, 2024 Category: Pathology Authors: Gabriella G álffy Éva Morócz R éka Korompay R éka Hécz R éka Bujdosó Rita Pusk ás T ímea Lovas Eszter G áspár Kamel Yahya P éter Király Zolt án Lohinai Source Type: research
Bruceantinol works as a CDK2/4/6 inhibitor to inhibit the growth of breast cancer cells
Chem Biol Interact. 2024 Apr 10:110999. doi: 10.1016/j.cbi.2024.110999. Online ahead of print.ABSTRACTBruceantinol (BOL), isolated from the dried fruit of the Brucea javanica (L.) Merr., exhibits cytotoxic effects on breast cancer cells. However, the underlying mechanism remains to be fully addressed. In this paper, the MCF-7 and MDA-MB-231 human breast cancer cell lines were used as experimental models to uncover how BOL inhibits breast cancer cell growth. The effects of BOL on cell growth, proliferation, the cell cycle, and apoptosis were investigated using the MTT assays, EdU incorporation assays, and flow cytometry, re...
Source: Chemico-Biological Interactions - April 12, 2024 Category: Molecular Biology Authors: Li Sun Yumeng Wang Jia Li Shiqing Xu Shuang Xu Jun Li Source Type: research
